Table 2.
NNTC cohort demographics with and without HIV brain pathology
| Overall (N = 589) | Parenchymal HIV brain pathology (N = 103) | No parenchymal HIV brain pathology (N = 486) | P value | |
|---|---|---|---|---|
| Age at death | .65 (WRT) | |||
| median (IQR) | 45 (39, 51) | 44 (39, 53) | 45 (39, 51) | |
| Sex (M, F) | .62 (FET) | |||
| Females | 101 (17%) | 24 (23%) | 77 (16%) | |
| Males | 488 (83%) | 79 (77%) | 409 (84%) | |
| Race/ethnicity | .83 (FET) | |||
| White | 255 (43%) | 43 (42%) | 212 (44%) | |
| Black | 141 (24%) | 24 (23%) | 117 (24%) | |
| Hispanic | 172 (29%) | 31 (30%) | 141 (29%) | |
| Unknown/other | 21 (4%) | 5 (5%) | 16 (3%) | |
| Mode of transmission | .58 (FET) | |||
| IDU | 165 (28%) | 28 (27%) | 137 (28%) | |
| M2M | 232 (39%) | 43 (41%) | 189 (39%) | |
| Heterosexual | 77 (13%) | 10 (10%) | 67 (14%) | |
| Blood prod rec. | 20 (3%) | 6 (6%) | 14 (3%) | |
| Other | 20 (3%) | 6 (6%) | 14 (3%) | |
| Unknown | 75 (13%) | 12 (11%) | 63 (13%) | |
| Duration of infection (years) | ||||
| median (IQR) | 11 (7, 15) | 11 (6, 14) | 11 (7, 15) | .67 (WRT) |
| Alive at study entry | .24 (FET) | |||
| Yes | 405 (69%) | 76 (74%) | 329 (68%) | |
| No (autopsy only) | 184 (31%) | 27 (26%) | 157 (32%) | |
| Year of death (1998–2007) | .89 (WRT) | |||
| median (IQR) | 2002 (2000 (2004) | 2002 (2000 (2004) | 2002 (2000 (2005) | |
| Length of study follow-up (months) (N = 405, excludes autopsy only patients) | .10 (WRT) | |||
| median (IQR) | 3 (0, 15) | 8 (0, 20) | 2 (0, 15) | |
| CD4 Nadir during follow-up (N = 395) | .003 (WRT) | |||
| Median (IQR) | 37 (7,142) | 15 (5, 68) | 48 (8, 148) | |
| Last log viral load within 6 mo. Of death (N = 371) | ||||
| Median (IQR) | 4.5 (2.6, 5.4) | 5.3 (4.3, 5.8) | 4.2 (≤ 2.6, 5.2) | < .001 (GWRT) |
| On study ARV regimens (N = 392) | .026 (FET) | |||
| PI/NRTI | 112 (29%) | 25 (32%) | 87 (28%) | |
| PI/NNRTI/NRTI | 85 (22%) | 10 (13%) | 75 (24%) | |
| NNRTI/NRTI | 47 (12%) | 5 (6%) | 42 (13%) | |
| NRTI only | 24 (6%) | 4 (5%) | 20 (6%) | |
| None | 124 (32%) | 34 (44%) | 90 (29%) | |
| Neurocognitive impairment (N = 336) | .71 (FET) | |||
| NP–normal | 41 (12%) | 5 (8%) | 36 (13%) | |
| Asymptomatic NPI | 18 (5%) | 4 (6%) | 14 (5%) | |
| Minor NCD | 71 (21%) | 16 (24%) | 55 (20%) | |
| HAD | 75 (22%) | 16 (24%) | 59 (22%) | |
| NPI–other | 131 (39%) | 25 (38%) | 106 (39%) | |
| Depression (N = 264) | .35 (FET) | |||
| MDD during study | 88 (33%) | 13 (25%) | 75 (35%) | |
| MDD in the past | 72 (27%) | 14 (27%) | 58 (27%) | |
| No MDD | 96 (40%) | 24 (48%) | 80 (38%) | |
Note. A summary of the demographic variables for the groups with and without HIV brain pathology. These include age at death, sex, race/ethnicity, mode of transmission, duration of infection, alive at study entry, year of death and length of study follow-up, CD4 nadir during follow-up, last viral load within 6 months of death, on study antiretroviral regimen, presence of neurocognitive impairment, and presence of major depressive disorder. Of these variables, only the on study antiretroviral regimen was significantly different between the two groups.
ARV = antiretroviral; IDU = intravenous drug user; M2M = male-to-male sexual encounter; IQR = interquartile range; NRTI = nucleoside reverse transcriptase inhibitor; NNRTI = non-NRTI; PI = protease inhibitor; NP = neuropsychological; NPI = neuropsychologically impaired; MCMD = minor cognitive motor disorder; HAD = HIV-associated dementia; MDD = major depressive disorder.